Good day, 360!

President Donald Trump is promising us that "The golden age of America begins right now” and that “America’s decline is over.” No matter what side of the political fence you are on, for America’s sake… let’s hope he’s right!

As for today… please join us for THIS special event:

FOCUS LIST🔎

HSDT - Up over 40% in the pre-market after announcing strong enrollment of its stroke pivotal study exceeding initial target 

TEM - Up over 17% in pre after Nancy Pelosi reported purchase of 50 Jan 2026 $20 Call options In Tempus AI on January 14

VATE - Up over 24% in pre after announcing its MediBeacon® Transdermal GFR System receives FDA approval to assess kidney function

HOTLIST🔥

HSDT - Up over 40% in the pre-market after announcing strong enrollment of its stroke pivotal study exceeding initial target  

Helius Medical Technologies Inc. (HSDT) is a a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits.

In the pre-market this morning, the company announced it has completed and far exceeded the initial target enrollment for its stroke registrational program. With 128 participants randomized to-date the program is on track to reach the maximum enrollment target of 150 participants by the end of January 2025.

The stroke registrational program is intended to demonstrate the safety and effectiveness of the novel Portable Neuromodulation Stimulator (PoNS®) for improving balance and gait deficits in stroke survivors.

Shares of HSDT traded up over 40% in the pre-market in reaction to the news.

The $1.09 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $1.24, $1.30 and then the pre-market high at $1.39. Beyond that, $1.45, $1.50, $1.70 and $2 come into play.

Below $1.09, targets to the downside are $1, $0.90, $0.85 and then a gap fill at $0.7510.

TEM - Up over 17% in pre after Nancy Pelosi reported purchase of 50 Jan 2026 $20 Call options In Tempus AI on January 14

Tempus AI Inc (TEM) operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties.

Earlier this morning it was disclosed that former House Speaker Nancy Pelosi reported the purchase of 50 Jan 2026 $20 Call options In Tempus AI on January 14. Having shown a phenomenal track record between herself and her husband in recent years in investments, the disclosure sent shares of TEM trading up over 17% in the pre-market.

The $41.39 area acted as support in the pre-market and now becomes a potential level of resistance.

Above it, targets to the upside are $42, $43, $44.50 and then the pre-market high at $45.25. Beyond that, $47 and $51 come into play.

Below $41.39, targets to the downside are $40.59, $38.50, $37.50, $36 and then a gap fill at $35.15.

VATE - Up over 24% in pre after announcing its MediBeacon® Transdermal GFR System receives FDA approval to assess kidney function

INNOVATE Corp. (VATE) through its subsidiaries, operates in infrastructure, life sciences, and spectrum areas in the United States.

In the after-hours Friday, the company announced that the U.S. Food and Drug Administration (FDA) has approved the MediBeacon® TGFR for the assessment of kidney function in patients with normal or impaired renal function.

Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function

The transdermal GFR (tGFR) methodology has been designed to be effective across the adult population without input of age, weight, sex, gender, race, or ethnicity

More than 800 million people have Chronic Kidney Disease (CKD), one of the world’s leading causes of mortality worldwide, with associated deaths increasing over the past two decades

Shares of VATE traded up over 24% in the pre-market in reaction to the news.

The $7.20 area acted as support in the pre-market and now becomes a potential level of resistance.

Above it, targets to the upside are $8, $8.20, $8.40 and then the pre-market high at $8.91. Beyond that, $9.56 and $10 come into play.

Below $7.20, targets to the downside are $6, $5.70 and then a gap fill at $5.11. 

MARKET NEWS 📰

Don't miss out on our MOBILE ALERTS!  Some of these alerts have rocketed 🚀past the MOON 🌝.  Text “RAGE” to 1-(888) 487-1534 📲.